FGF18 as a potential biomarker in serous and mucinous ovarian tumors

Tumor Biology

Volumn 37, Issue 3, 2016, Pages 3173-3183

  El Gendi, Saba ^a   Abdelzaher, Eman ^a   Mostafa, Mohamed Farouk ^a   Sheasha, Ghada Abu ^b  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

FGF18; MVD; Ovarian tumors; Patients outcome

Indexed keywords

CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CAPILLARY DENSITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS OVARIAN TUMOR; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEROUS OVARIAN TUMOR; AGED; BIOSYNTHESIS; CANCER STAGING; COLLOID CARCINOMA; CYSTADENOCARCINOMA; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VASCULARIZATION; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84944707858     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4129-0     Document Type: Article

References (25)

1. Prat J. Pathology of the ovary. Philadelphia: Saunders; 2004.
2. Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI, et al. Surface epithelial-stromal tumours (Ch 2: tumours of the ovary and peritoneum). In: Tavassoli FA, Devilee P, editors. World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC; 2003. p. 117–45.
3. Mokhtar N, Gouda I, Adel I. Malignant female genital tumors. In: Mokhtar N, Gouda I, Adel I, editors. Cancer pathology registry 2003-2004 and time trend analysis. Cairo: Elsheraa; 2007. p. 77–82.
4. Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol. 2011;42:918–31.
5. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20:1319–30.
6. Shih I-M, Kurman RJ. Ovarian tumorigenesis- a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–8.
7. McCluggage WG. My approach to and thoughts on typing of ovarian carcinomas. J Clin Pathol. 2008;61:152–63.
8. Vang R, Shih IM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267–82.
9. McCluggage WG. The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol. 2010;22:462–72.
10. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol. 1996;20:1331–45.
11. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007;25:2281–7.
12. Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest. 2013;123:4435–48.
13. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–49.
14. Haque T, Nakada S, Hamdy RC. A review of FGF18: its expression, signaling pathways and possible functions during embryogenesis and post-natal development. Histol Histopathol. 2007;22:97–105.
15. Marie PJ. Fibroblast growth factor signaling controlling osteoblast differentiation. Gene. 2003;316:23–32.
16. Moore EE, Bendele AM, Thompson DL, Littau A, Waggie KS, Reardon B, et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthri Cartilage. 2005;13:623–31.
17. Antoine M, Wirz W, Tag CG, Gressner AM, Wycislo M, Müller R, et al. Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation. Biochem Biophys Res Commun. 2006;346:224–33.
18. Liu Z, Lavine KJ, Hung IH, Ornitz DM. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol. 2007;302:80–91.
19. Franco-Montoya ML, Boucherat O, Thibault C, Chailley-Heu B, Incitti R, Delacourt C, et al. Profiling target genes of FGF18 in the postnatal mouse lung: possible relevance for alveolar development. Physiol Genomics. 2011;43:1226–40.
20. Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin Y-M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. Cancer Res. 2003;63:6116–20.
21. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9(5):e1001216. doi:10.1371/journal.pmed.1001216.
22. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of the female reproductive organs. 4th ed. Lyon: IARC; 2014.
23. Saddick SY. Update on epithelial ovarian cancer (EOC). Types, origin, molecular pathogenesis, and biomarkers. Life Sci J. 2014;11:1–16.
24. Jaime Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.
25. Sehgal S, Goyal P, Agarwal R, Singh S, Kumar A, Gupta R, et al. Differences in the angiogenesis of benign and malignant ovarian surface epithelial tumors demonstrated by microvessel density and immunohistochemistry. J Interdiscipl Histopathol. 2013;1:145–52.